Overview

Onyx Biotec Limited is a pharmaceutical contract manufacturing organization (CDMO) that produces sterile water for injections, dry powder injections, and dry syrups for B2B clients, offering end-to-end development, manufacturing, and regulatory dossier filing. It operates two WHO-GMP certified plants in Solan, Himachal Pradesh, expanded from two lines in 2010 to six by 2020, and opened a second unit in 2023 for dry powder injections and syrups. Its strengths include fully certified facilities with in-house regulatory filing, a client base of over 100 including Sun Pharma, Mankind, Macleods, and Glenmark, and ongoing capacity expansion with a dedicated unit for dry powders. The company plans to use IPO proceeds to upgrade capacity for large-volume parenterals and high-speed packaging, repay debt, and fund growth in global generic manufacturing.

Significant Headcount Growth